Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer

BACKGROUND: In locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of cancer therapy, though whether it is applic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiangmei, Li, Jingping, Yang, Qing, Wang, Yanfang, Li, Xinhui, Liu, Yunjiang, Shan, Baoen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576007/
https://www.ncbi.nlm.nih.gov/pubmed/33145271
http://dx.doi.org/10.21037/atm-20-3773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576007/
https://www.ncbi.nlm.nih.gov/pubmed/33145271
http://dx.doi.org/10.21037/atm-20-3773

Ejemplares similares